01Understand the extension rather than doubling the label

The IUPHAR/BPS receptor-family account describes somatostatin-14, also called SRIF-14, as a cyclic 14-residue peptide. Somatostatin-28 contains that region with an additional 14 residues at the amino terminus.IUPHAR/BPS — Somatostatin receptor family introduction (opens in a new tab)

The two forms arise through processing of a common precursor. The same account identifies five somatostatin receptor subtypes, so a phrase such as somatostatin receptor should be resolved to the subtype where the experiment permits.IUPHAR/BPS — Somatostatin receptor family introduction (opens in a new tab)

A shared sequence region explains why the forms are related. It does not establish the same potency at every receptor or the same distribution across tissues.

02Read older precursor terminology in its historical context

Schally and colleagues’ 1980 paper isolated a 28-residue peptide from pig hypothalamus and called it pro-somatostatin. The published sequence contains the somatostatin region at its carboxyl-terminal end.Schally and colleagues — Isolation of the 28-residue pro-somatostatin (opens in a new tab)

The modern precursor terminology in the curated receptor account refers to a substantially longer preproprotein and its processed precursor. An older title using pro-somatostatin should therefore not automatically be assigned to that larger modern sequence record.IUPHAR/BPS — Somatostatin receptor family introduction (opens in a new tab)

Use the residue count and sequence in the original methods to resolve what the authors meant. Historical names can preserve a hypothesis about biosynthesis rather than the final terminology adopted later.

03Relative potency depends on the secretion measured

Mandarino and colleagues’ 1981 in-vitro study compared somatostatin forms in insulin and glucagon secretion experiments. The longer forms more strongly inhibited insulin release, while somatostatin-14 preferentially inhibited glucagon release in the reported system.Mandarino and colleagues — Selective insulin and glucagon secretion effects (opens in a new tab)

This is an endpoint-specific comparison. Summarising it as the longer peptide is stronger would omit the glucagon result and conceal what the experiment actually distinguished.

It also shows why twice the residue count cannot be interpreted as twice the biological effect. Sequence length is a structural quantity; potency is estimated from a defined response under defined assay conditions.

When comparing another paper, check the tissue preparation, receptor context, stimulus and concentration basis. Equal mass and equal molar concentration are not the same comparison for two peptides of different molecular masses.

04Detecting a circulating form is a different question

Polonsky and colleagues’ 1983 human study separated plasma somatostatin-like immunoreactivity chromatographically. Peaks coeluting with 14- and 28-residue reference materials changed after a mixed meal, while a larger void-volume signal did not show that response.Polonsky and colleagues — Plasma somatostatin-28 after feeding (opens in a new tab)

The result supported the presence and meal responsiveness of a circulating 28-residue form. It did not establish that every somatostatin-reactive plasma signal represented that molecule.

Nor does a circulating concentration identify the local receptor response in each tissue. Detection, molecular assignment and physiological effect are connected questions that still require different measurements.

For literature notes, retain the form, sample compartment and endpoint together. That keeps this endogenous reference useful while leaving synthetic analogue formulations and therapeutic decisions to their own product-specific evidence.